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Summary
Observational cohort studies of individuals with chronic disease provide information on rates of
disease progression, the effect of fixed and time-varying risk factors, and the extent of heterogene-
ity in the course of disease. Analysis of this information is often facilitated by the use of multistate
models with intensity functions governing transition between disease states. We discuss modeling
and analysis issues for such models when individuals are observed intermittently. Frameworks for
dealing with heterogeneity and measurement error are discussed including random effect models,
finite mixture models, and hidden Markov models. Cohorts are often defined by convenience and
ways of addressing outcome-dependent sampling or observation of individuals are also discussed.
Data on progression of joint damage in psoriatic arthritis and retinopathy in diabetes are analysed
to illustrate these issues and related methodology.
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1 INTRODUCTION
Chronic disease processes are often complex, and feature periods of acute disease activity and gradual
deterioration in function of one or more organ systems. Cohort studies can offer important information
about these sorts of processes through careful follow-up of affected individuals over time. Such
studies have played a central role in the identification of demographic, genetic and environmental
factors associated with disease onset and progression, the assessment of therapeutic interventions,
and the specification of models for prediction at the individual or population level.
Multistate stochastic models offer an appealing framework for the analysis of disease activity and
progression, of related events, and of concomitant time-varying risk factors. Our purpose is to discuss
the utility of multistate models in studies of chronic disease, to highlight some of the modeling issues
arising from such studies, and to consider ways in which these challenges may be addressed within
the multistate framework.
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When disease status is measured on an ordinal scale in progressive conditions, intensity-based
methods offer a convenient and informative way to model dynamic aspects of disease and to identify
prognostic variables. This strategy has been widely used, in studies of psoriatic arthritis (O’Keeffe
et al., 2011), hepatitis (Sweeting et al., 2006), complications from diabetes (Al-Kateb et al., 2008),
HIV infection (Gentleman et al., 1994), bone marrow transplantation (Keiding et al., 2001) and age-
related cognitive decline and dementia (Tyas et al., 2007). Many challenges arise in the use of such
models, however. Often there is considerable variability between individuals in the nature and rate of
progression, making it difficult to specify plausible models. This is particularly true when states are
based on categorization of continuous measures of disease severity. Imperfect measurement of disease
status can lead to apparent improvement in what is believed to be a progressive condition across
consecutive observation times. Fitting even simple models can be challenging when data are only
collected at random and variably spaced assessment times, and this is particularly true when modeling
the effects of concomitant variables which are only observed intermittently. Further challenges arise
with other types of missing information, when modeling relationships between different aspects of
disease status, and when dealing with the effects of disease-related selection or follow-up.
We now introduce two studies that illustrate and motivate subsequent development.
EXAMPLE 1.1 THE UNIVERSITY OF TORONTO PSORIATIC ARTHRITIS COHORT
Psoriatic arthritis (PsA) is an immunological disease associated with considerable joint pain, inflam-
mation and destruction which can ultimately lead to serious disability and poor quality of life (Chan-
dran et al., 2010). The Centre for Prognosis Studies in Rheumatic Disease is a tertiary referral center
at the Toronto Western Hospital which treats patients with a variety of rheumatic diseases and main-
tains a clinic registry of patients with psoriatic arthritis. This cohort was established in 1976 and has
been recruiting and following patients since its formation; today it is one of the largest cohorts of
patients with PsA in the world.
Upon entry to the clinic patients undergo a detailed clinical and radiological examination and pro-
vide serum samples which are subsequently stored. Follow-up clinical and radiological assessments
are scheduled annually and biannually, respectively, in order to track changes in joint damage, func-
tional ability, and quality of life. Additional serum samples are taken at follow-up clinic visits to
measure dynamic markers of inflammation and to store for future analysis of genetic data. To date,
1191 patients have been recruited and there is a median of 4.84 years of follow-up and a median of
6 clinical follow-up assessments. Given this data, disease progression can be modeled in a number
of ways including the development of newly damaged joints (Gladman et al., 1995; Sutradhar and
Cook, 2008), the involvement of particular types (e.g. spinal) of joints (Tolusso and Cook, 2009), or
progression to a state of clinically important damage (Chandran et al., 2012).
EXAMPLE 1.2 DCCT/EDIC STUDY OF TYPE 1 DIABETES
The Diabetes Control and Complications Trial (DCCT) was a randomized study that involved Type 1
diabetics, and ran from 1984 to 1993. Subjects in the trial were randomized to an intensive therapy
treatment arm or to a conventional therapy control arm. The intensive therapy treatment was designed
to achieve and maintain near-normal glucose levels, whereas the conventional therapy was designed
to prevent hyperglycemic symptoms (The Diabetes Control and Complications Trial Research Group,
1993). The DCCT showed that the intensive therapy was associated with a significant reduction in the
onset of diabetic retinopathy and neuropathy. After it was terminated in 1993, most subjects (1375
of 1441) joined the observational Epidemiology of Diabetes Interventions and Complications (EDIC)
study, which began in 1994. Subjects in the DCCT were seen approximately every 3 months, and eye
and kidney measurements were taken every 6 months; during EDIC these measurements are taken
roughly every two years. The degree of retinopathy was expressed on the ordinal ETDRS scale (Early
Treatment Diabetic Retinopathy Study Research Group, 1991). Measurements of renal function in-
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cluded urinary albumin excretion rates (AER) and two states, persistent microalbuminaria and severe
nephropathy, were based on this (Al-Kateb et al., 2008). Many fixed covariates and time-varying
biomarkers were also measured on each individual; the most important biomarker is glycosylated
hemoglobin (HbA1c), which measures average blood glucose over a prolonged period up to the mea-
surement date. In addition to establishing the value of intensive therapy for the control of HbA1c
in Type 1 diabetics, the DCCT and EDIC studies have produced information on complications from
diabetes and on biological and genetic factors associated with progression.
In the remainder of the paper we discuss several issues in the context of multistate models. They
include challenges in modeling heterogeneous disease processes and in dealing with missing data
arising from intermittent observation of individuals; alternative models for individual or joint pro-
cesses; and the possibility that selection or observation of individuals is outcome-dependent. Section
2 reviews likelihood function construction for multistate models, emphasizing the case of intermittent
observation. Section 3 discusses several aspects of modeling progressive disease processes, includ-
ing families of multistate models, heterogeneity versus process dynamics, models with latent (unob-
served) components, and ways of handling time-varying covariates. Section 4 considers models for
multiple processes. Section 5 illustrates modeling and analysis in the psoriatic arthritis and Type 1
diabetes cohorts introduced in Examples 1.1 and 1.2. Section 6 gives brief discussions of outcome-
dependent selection or observation of processes, and Section 7 contains some concluding remarks and
notes areas where further development is needed.
2 LIKELIHOOD FOR MULTISTATE ANALYSES
2.1 LIKELIHOOD CONSTRUCTION WITH RIGHT-CENSORED DATA
Consider a multistate model with K states where Z(t) indicates the state occupied at time t and
{Z(s), 0 < s} is the associated stochastic process. States are ideally formed based on well-defined
stages of the disease process. Sometimes it is appropriate to include one or more absorbing states
to reflect death, different causes of death, or other reasons for termination of the disease process.
Let X(t) denote a p × 1 vector of left-continuous, time-varying covariates. The history for the two
processes is denoted H(t) = {(Z(s), X(s)), 0 < s < t}. We may specify intensity functions for the
process {Z(s), 0 < s} as
λk`(t|H(t)) = lim
∆t↓0
P (Z(t+ ∆t−) = `|Z(t−) = k,H(t))
∆t
(1)
where ` = k (Andersen et al., 1993).
It is often helpful to express models equivalently in terms of counting processes, particularly
when data are right-censored. Let dNkl(t) = 1 if a transition from state k to l occurs at time
t and let dNk`(t) = 0 otherwise, Nkl(t) =
∫ t
0
dNkl(s) count the number of k → l transitions
over (0, t] and let {Nkl(s), 0 < s} be the corresponding right-continuous counting process. Let
Nk(t) = (Nk1(t), . . . , NkK(t))
′ denote the multivariate counting process of transitions out of state k
and N(t) = (N ′1(t), . . . , N
′
K(t))
′. With counting process notation the intensity can be alternatively
expressed as
λk`(t|H(t)) = lim
∆t↓0
P (∆Nk`(t) = 1|Yk(t) = 1,H(t))
∆t
,
where ∆Nk`(t) = Nk`(t + ∆t−) − Nk`(t−) counts the number of k → ` transition over [t, t + ∆t)
and Yk(t) = I(Z(t−) = k) indicates whether an individual is at risk of a transition out of state k at t.
To accommodate right-censoring times C > 0 we denote Y¯k(t) = I(t ≤ C)Yk(t).
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The partial likelihood for the parameters specifying the intensities is
L ∝
K∏
k=1
∏
`∈Sk
Lk`
for a given individual, where Sk is the set of states ` for which λk`(t|H(t)) > 0,
Lk` =
∏
s∈Dk`
λk`(s|X(s),H(s)) exp
(
−
∫ ∞
0
Y¯k(u)λk`(u|X(u),H(u))du
)
,
and Dk` is the set of transition times observed from state k to state `, ` ∈ Sk, k = 1, 2, . . . , K
(Andersen et al. 1993; Cook and Lawless, 2007). This likelihood is similar to those used in survival
analysis and this connection enables us to fit multistate models using software for survival data.
2.2 LIKELIHOOD WITH INTERMITTENT OBSERVATION
Now we consider the case of intermittent inspection and consider the likelihood contribution from a
single individual. Let v0 < v1 < · · · < vn denote the times of n clinic visits where assessments are
carried out and the health state and covariates are measured. Let H(vr) = {(z(vs), x(vs), vs), s =
0, 1, 2, . . . , r − 1} denote the history of the observed data under this inspection process. This is
sometimes referred to as panel data in the literature (e.g. Kalbfleisch and Lawless, 1985). In this case
the full likelihood is
L ∝ P (Z(v0), X(v0), V0 = v0)
n∏
r=1
P (Z(vr), X(vr), Vr = vr|H(vr)) .
It is common to condition on the state and covariate values at the initial assessment, in which case we
omit the term P (Z(v0), X(v0), V0 = v0); when v0 = 0 this corresponds to the onset of the process
so if P (Z(0) = 1|X(0)) = 1, this omission is innocuous. More generally, there can be some loss
in efficiency, particularly when the number of follow-up assessments is low, but this information can
only be extracted with strong assumptions about the initial conditions.
Premature loss to followup (LTF) is also common, in which case the final observation time vn
may precede an intended final assessment time v. We assume the “sequential missingness at random”
(SMAR) condition (Hogan et al., 2004) which requires that if an individual is observed up to vr−1,
then conditional on the event history at that time, the probability they are LTF and not observed at vr
cannot depend on events in [vr−1, vr). In studies with widely spaced visit times this condition is often
violated to some extent. We discuss this further in Section 6.1; see also Lawless (2013).
Under the assumption Vr⊥Z(vr), X(vr)|H(vr),
P (Z(vr), X(vr), Vr = vr|H(vr)) = P (Z(vr), X(vr)|vr, H(vr))P (Vr = vr|H(vr)) ,
and if the inspection process is non-informative, we disregard the second term on the right (Gru¨ger et
al., 1991). The factorization
P (Z(vr), X(vr)|vr, H(vr)) = P (Z(vr)|vr, H(vr))P (X(vr)|vr, Z(vr), H(vr))
is typically adopted for modeling, since it is natural to use covariate information at vr−1 to model the
state occupied at vr. In this case we may focus on the partial likelihood (Cox, 1975) based on the first
components of this factorization,
n∏
r=1
P (Z(vr)|H(vr)) . (2)
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In (2) and henceforth we omit vr in the conditioning event for notational convenience, but it is implic-
itly present.
When assessment times are evenly spaced and common to all individuals, discrete time models
offer a convenient framework. When there is considerable variation in the spacing of assessment
times, models for continuous-time processes are usually necessary, and in this case dealing with time-
varying covariates under intermittent inspection is challenging. If the covariates are discrete, one
approach is to model the covariate process jointly with the outcome (Tom and Farewell, 2011). If for
example, X(t) is an indicator of whether a concomitant comorbidity has developed, joint models with
an expanded state space encompassing both the covariate and outcome data are useful. Continuous
time-varying covariates are much more difficult to deal with and these will typically require stronger
assumptions to specify tractable joint models. We return to this in Section 3.6.
3 CONSIDERATIONS IN MODELING PROGRESSIVE PROCESSES
3.1 MODELS FOR PROGRESSIVE DISEASE
We consider multi-state models with K − 1 transient states and a single absorbing state representing
death or another event that terminates the process. The emphasis here is on chronic conditions for
which progression tends to occur over time, in which case we often assume that transitions from a
transient state can only be made to the next highest state or the absorbing state; see Figure 1. In some
settings, entries to state K may only come from state K − 1.
1 2
K
3 K−1
Figure 1: Diagram of a progressive multistate model with an absorbing state
It is common in longitudinal studies for an individual to show improvement from one visit to the next,
so that Z(vr) < Z(vr−1); this may be due to random fluctuations in a person’s status, to misclassifica-
tion of the discrete disease states, or to errors in the measurement of an underlying continuous score.
A common ad hoc convention involves defining states operationally based on sustained observation
above a threshold for a prescribed period of time or number of visits. Progression of diabetic retinopa-
thy, for example, has sometimes been defined as occuring when a person has ETDRS scores on two
consecutive visits that are 3 or more grades higher than the score at the baseline visit (The Diabetes
Control and Complications Trial Research Group, 1993). This approach ties the state definitions to
the sequence of visit times {vr, r = 0, 1, 2, . . .}, which can be undesirable when times between visits
are highly variable. It might also be undesirable for processes in which significant real improvement
may occur. In such cases we may prefer to allow transitions in both directions between adjacent tran-
sient states; this complicates model fitting and analysis but provides a more realistic representation of
the observed disease process. Another option is to consider the “true” disease process {Z(s), 0 < s}
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to be as in Figure 1 but unobserved, with the observed process, denoted {Z∗(s), 0 < s}, related to
the true process. Hidden Markov models (HMMs), in which {Z(s), 0 < s} is a Markov process,
have been used by several authors (e.g. Satten and Longini, 1996; Bureau et al., 2003; Jackson and
Sharples, 2002) and can be fit with the msm package in R (Jackson, 2011). We discuss these in Section
3.5.
A thorough comparison of competing models and of estimability issues with intermittent obser-
vation would be valuable. We compare different approaches for analysing diabetic retinopathy in
Section 5.2.
3.2 TIMES SCALES, FAMILIES OF MODELS AND MODEL FITTING
The types of models used for disease processes may depend on the main objectives of analysis. If
we aim to understand individual process dynamics and related factors, then models whose intensi-
ties reflect such dynamics are desirable. However, if the main objective is to assess a treatment or
intervention then models which consider marginal process characteristics such as time of entry to a
particular state are preferred. The reason for this is that intensity-based models which condition on
previous event history confound treatment covariates with previous history, thus making interpreta-
tion of treatment effects problematic. For more discussion see Aalen et al. (2008, Ch. 8) and for
examples of marginal analysis, Cook et al. (2009).
In modeling transition intensities (2), an initial consideration is whether to emphasize age of a
process (“global” time) or the duration of time spent in each state visited. Markov models are basic
for the former situation and semi-Markov models for the latter. With Markov models the transition
intensities take the form λk`(t|H(t), X) = qk`(t;X), where for now we restrict attention to fixed
covariatesX . This requires specification of a time origin (t = 0) that is comparable across individuals;
it particularly affects relative risk modeling of covariate effects. For example, in the DCCT/EDIC
study of Example 1.2 we could let t represent (a) age, (b) time since onset of diabetes, or (c) time
since entry to the study. Because individuals were randomized to treatment at study entry, (c) is
preferable when analyses are directed at treatment comparisons, but this may not provide the most
appropriate or parsimonious model of process dynamics. Pencina et al. (2007) provide some general
discussion of time origins and relative risk models.
Markov models with fixed covariates can be fitted fairly easily with intermittently observed data.
Estimation of model parameters by maximum likelihood is based on the likelihood function (2), which
for Markov models depends only on transition probabilities P (Z(vr) = `|Z(vr−1) = k,X). Time-
homogeneous models for which qk`(t;X) = qk`(X) are especially straightforward. In this case the
K ×K transition probability matrix P(t;X) with entries pk`(t;X) = P (Z(s+ t) = `|Z(s) = k;X)
is given by the matrix exponential function,
P(t;X) = exp{tQ(X)} , (3)
where Q(X) is the K ×K matrix with (k, `) entries qk`(X) for k 6= `, and qkk(X) = −Σ` 6=kqk`(X)
as the diagonal entries (Cox and Miller, 1965). Kalbfleisch and Lawless (1985) discuss computation
of (3) and algorithms for maximizing the associated likelihood function. This has been implemented
in software packages, including the msm package in R (Jackson, 2011) which we use later.
Non-homogeneous Markov models with intensities qk`(t;X) are somewhat harder to fit with in-
termittent observation and general software is not available. However, by using the product-integral
representation for a transition probability matrix P (s, t;X), (e.g. Aalen et al., 2008, Section A.2.4),
P (s, t;X) =
∏
(s,t]
{I+Q(u;X) du} , (4)
where I is a K × K identity matrix, we can approximate transition probabilities closely by discrete
approximation. See Titman (2011) for a similar approach in terms of the Kolmogorov differential
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equations for the process (e.g. Aalen et al., 2008, Section A.2.3). A simple and convenient alternative
is to assume transition intensities are piecewise constant; the msm package can deal with this. Models
with time-varying covariates are more complicated to handle when the covariates are observed only
intermittently. It is generally necessary to make simplifying assumptions about their behavior or to
model them, and we defer discussion to Section 3.6.
Models in which intensities (2) depend on time since entry to a state are also harder to handle with
intermittent observation because the time of entry is usually unobserved. For progressive models as
in Figure 1, however, it is possible to obtain transition probabilities needed for the likelihood (2);
see Titman and Sharples (2010a) and Yang and Nair (2011) for recent discussions of semi-Markov
models in this context.
Realistically, the transition intensities for a process may depend on other aspects of the history
besides t, covariates and time since entry to the current state. Aalen et al. (2008, Chapters 8 and 9)
provide an informative discussion of process dynamics and how they can be modeled. With intermit-
tently observed continuous time processes it is difficult or impossible to fit complex models, although
progress is sometimes possible for progressive models. In cases where the times between successive
visits are more or less constant across individuals, a viable option is to use discrete time models for
Z(vr), r = 0, 1, . . . , n; Bacchetti et al. (2010) consider logistic regression models with dependence
on process history in this setting.
Finally, we note the importance of initial conditions in settings where individuals are not all fol-
lowed from the origins of their processes. Initial conditions include baseline covariates and relevant
process history such as the duration of the disease process at the start of followup. Failure to ad-
just for important factors can bias conclusions, especially in observational studies. For example,
Prentice et al. (2005) discuss time-dependent adverse health effects of hormone therapy (HT) for
post-menopausal women that were seen in a Women’s Health Initiative study where women were
randomized to receive HT or a placebo at the start of followup. Previous observational studies in
which there was insufficient adjustment for the prior duration of HT conversely indicated beneficial
effects, in contradiction to the randomized trial. Relevant initial information should be collected in
observational studies; if it is not, then we must rely on modeling assumptions.
3.3 HETEROGENEITY VERSUS PROCESS DYNAMICS
Fixed covariates (e.g. genetic variables, family history) that help explain variation in the course of
disease across individuals are of considerable interest. The effects of such covariates are necessarily
confounded to some extent with the dependence on the process history when process intensities are
considered. Random effects are sometimes used in multistate models to account for unexplained
heterogeneity (e.g. Lin et al., 2008; Mandel and Betensky, 2008; O’Keeffe et al., 2013) and their
effects can also be hard to distinguish from the effects of process history. As an illustration, consider
a 3-state progressive model and suppose that conditional on an unobservable random effect α, the
conditional transition intensities are λ12(t|H(t), α) = αλ12 and λ23(t|H(t), α) = αλ23. If α has
a gamma distribution with mean 1 and variance φ, after marginalizing over the random effect the
“observable” intensity λ23(t|H(t)) is,
λ23(t|H(t)) = P (dN23(t) = 1|Y2(t) = 1, t1) /dt
=
(1 + φ)λ23
1 + φ{λ12t1 + λ23(t− t1)} (5)
where t1 is the transition time from state 1 to state 2. The random effect model is therefore equivalent
to a model with a very specific type of dependence on H(t) given by (5). This model has also been
considered by Aalen et al. (2008, pp. 262–263).
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More generally, covariates, their effects, and random effects may all vary with time. A decon-
struction of process dynamics that clearly distinguishes covariate effects, random effects and history-
dependence is unachievable without strong assumptions about the mathematical form of the model. In
settings where process dynamics and prediction are of interest and fairly complete data are available
on process histories, we might prefer to develop intensity-based models and to add random effects
only if they improve significantly the predictive power of the model. Given the incompleteness of
process history information in some studies, particularly those with intermittent observation, random
effects can offer a tractable and convenient approach. For example, the intensity function (5) is unus-
able if we do not observe (or know to a reasonable approximation) the transition time ti1. If we use the
random effects formulation on the other hand, we can take the likelihood function for an individual
conditional on their random effect α, and then integrate it with respect to α; this is tractable.
Aalen et al. (2008, Ch. 7 and 8) provide a lucid discussion of the issues in this section. On a final
important point not discussed by them, we note that random effects modeling can be problematic
when an individual is followed from a time v0 at which their disease process has been underway for
some time. In that case the distribution of a fixed random effect α will in general depend on process
historyH(v0) prior to v0; this is frequently ignored, with a single distribution assumed for the random
effects of all individuals. For additional discussion, see Lawless and Fong (1999).
3.4 FINITE MIXTURE MODELS
Continuous mixtures as in the preceding section involve very particular specifications on the nature of
the heterogeneity and sometimes discrete mixtures are preferable. In many contexts, the proportion of
individuals remaining progression-free is much higher than would be expected from a given model.
This type of heterogeneity is naturally modeled by allowing a fraction of the population to be at zero
risk of progression. A mixture model can be specified in this context with a Bernoulli random variable
α, where P (α = 1) = pi = 1 − P (α = 0). Such models are called mover-stayer models (Goodman,
1961; Frydman, 1984) since individuals will either be “movers” who transition through the process,
or “stayers” who do not.
A natural generalization of the mover-stayer model is to accommodateG classes labeled 1, 2, . . . , G
where individuals in the same class experience a disease course governed by a common process.
We let W be a latent random variable indicating the sub-population to which a particular individ-
ual belongs; that is, W = g if the individual belongs to class g, and P (W = g|X; γ) = pig(X),
g = 1, 2, . . . , G, with
∑G
g=1 pig(X) = 1. The disease process in the population is then governed by
a mixture of the class-specific processes. Estimating the number of such classes is challenging and
we focus on the case where this is specified in advance. Accommodation of distinct classes is often
motivated by apparent clusters of life history paths that share similar features, evident from exam-
ination of raw data. In many cohort studies, for example, some individuals are seen to experience
rapid progression, some progress at much slower rates and some may not progress even after exten-
sive follow-up. It is most appropriate to consider mixture models when there is evidence of distinct
clusters after adjusting for important prognostic variables.
To allow the intensity for transitions from state k to ` to differ across classes we let
λk`(t|H(t),W = g) = λ(g)k` (t|H(t); θg)
denote the intensity for class g where θg denotes the set of parameters governing the disease process,
g = 1, . . . , G, with θ = (θ′1, . . . , θ
′
G)
′, and ψ = (θ′, γ′)′. The resultant complete data likelihood
(assuming W is observed) is
Lcomp(ψ) ∝
G∏
g=1
{
Lg(θg)pig(γ)
}I(W=g)
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where Lg(θg) is of the form (2) but with the probabilities evaluated according to the class g model.
The structure of this likelihood suggests the use of an EM algorithm for estimation. If ψr denotes the
estimate of ψ obtained at the rth iteration,
ωrg = P (W = g|H(∞);ψr) =
Lg(θ
r
g)pig(X|γr)∑G
g=1 Lg(θ
r
g)pig(X|γr)
,
and Qψ;ψr = E(logLcomp(ψ)|H(∞);ψr), we obtain Q(ψ;ψr) = Q1(θ;ψr) +Q2(γ;ψr) where
Q1(θ;ψ
r) =
G∑
g=1
ωrg logLg(θg) ,
Q2(γ;ψ
r) =
G∑
g=1
ωrg log pig(X; γ) .
Under a Markov model for each class maximization ofQ1(θ;ψr) is straightforward. let pk`(s, t|X,W =
g; θg) = P (Z(t) = `|Z(s) = k,X,W = g; θg). At the rth iteration of the EM algorithm we can then
write (for progressive models)
Q1(θ;ψ
r) =
G∑
g=1
n∑
r=1
K−1∑
k=1
K∑
`=k
[ωrg · nk` · logPk`(vr−1, vr|X; θg) ,
which can be maximized separately for each θg using pseudo-transition counts ωrg ·nk` and the Fisher-
scoring algorithm of Kalbfleisch and Lawless (1985).
Such models have considerable appeal in their flexibility. They can, for example, involve strat-
ification so that in the multiplicative framework, baseline intensities can differ across classes but
regression coefficients may be common. Tests for homogeneity of covariate effects can likewise be
carried out. In some classes, some transition intensities may be estimated to be zero, suggesting that
individuals are at negligible risk of certain events. In fact the models for the different classes may
be very different in nature; some classes may involve Markov assumptions and others could involve
semi-Markov assumptions. Such hybrid models do not seem to have received much attention in the
literature.
Care is needed in fitting these models, with restrictions on parameter values typically needed
to avoid multimodal likelihoods. Considerable thought must also go into how best to incorporate
covariate effects in finite mixture models. While in theory covariates may be used to model both class
membership and the transition intensities, parameter estimation can be difficult when one or more
covariates appear in both parts of the model. Many questions are naturally addressed by modeling
only class membership as a function of covariates.
3.5 HIDDEN MARKOV MODELS
When it is difficult to accurately classify individuals, disease status may be imperfectly recorded. In
disease processes observed through radiological examination, for example, quality of radiographs,
ambiguous definitions of states, and inter- or intra-observer variation may lead to misclassification
of states. In these settings it is common to adopt a model based on an underlying process and a
misclassification model. As before we let Z(vr) represent the true state occupied at time vr, but now
we let Z∗(vr) denote the state recorded at vr. With a perfect classification procedure P (Z(vr) =
Z∗(vr)|x) = 1, but more generally we let ζkh = P (Z∗(s) = k|Z(s) = h, x) denote the conditional
probability that an individual is recorded to be in state k given they are in state h at time s;
∑K
k=1 ζkh =
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1, for h = 1, 2, . . . , K. In this case the process {Z(s), 0 < s} is latent (unobserved) or “hidden” and
the data relate to {Z∗(s), 0 < s}.
With fixed covariates we let H(vs) = {(Z(vs), vs), s = 1, 2, . . . , r − 1, X} denote the history of
the latent states, covariates, and observed inspection times. Let H∗(vr) = {(Z∗(vs), Z(vs)), vs, s =
1, 2, . . . , r − 1, X} denote the history of the observed and latent processes. We make the following
assumptions:
Assumption A.1 P ((Z(vr), vr)|H∗(vr)) = P ((Z(vr), vr)|H(vr)),
Assumption A.2 P (Z∗(vr)|Z(vr), vr, H∗(vr)) = P (Z∗(vr)|Z(vr)).
Assumption A.1 states that the inspection time and state occupied at the next assessment are
conditionally independent of the recorded states given the history of the true states, covariates, and
past inspection times. This is most reasonable in settings where individuals are passively observed
and no potentially influential actions are taken as a consequence of the assessments. It may be less
plausible in cohorts of patients in a clinic that provides routine medical care. Assumption A.2 states
that the classification of the state occupied at each inspection time depends only on the current true
state and possibly covariates but is conditionally independent of the observation process and prior
recorded and true disease states.
Then, conditioning on the fixed covariates and the first assessment at v0 = 0, a complete data
likelihood can be written as
Lc ∝ P (Z∗(v0), Z(v0)|X, v0)
n∏
r=1
P (Z∗(vr), Z(vr), vr|H∗(vr))
= P (Z∗(v0)|Z(v0), X, v0)P (Z(v0)|X, v0)
n∏
r=1
P (Z∗(vr)|Z(vr), vr, H∗(vr))P (Z(vr), vr|H∗(vr))
which by Assumptions A.1 and A.2 we write as
Lc ∝
[
P (Z∗(vr)|Z(vr), X)
n∏
r=1
P (Z∗(vr)|Z(vr), X)
]
[
P (Z(v0)|X, v0)
n∏
r=1
P (Z(vr), vr|H(vr))
]
(6)
The observed data likelihood can be obtained by summing (6) over all possible realization of {Z(vr), r =
0, 1, . . . , n}, and this is done in Jackson and Sharples (2002), Jackson et al. (2003), and the msm pack-
age. A EM algorithm can alternatively be used since the complete data likelihood factors into two
relatively simple parts; the first term in (6) denoted by L∗c contains the parameters of the misclassifica-
tion distribution, and the second term denoted by L is indexed by the parameters of the latent process
of interest. It is important to note, however, that at the E-step the expectation of logLc is with respect
to the entire path {Z(vr), r = 0, 1, . . . , n} since none of these values are observed. The Kalman
filter offers an alternative computationally convenient framework for estimation in this setting (e.g.
Fahrmeir and Tutz, 2001, Ch. 8).
With limited sample sizes, estimation of the misclassification probabilities and the transition prob-
abilities are confounded to some extent, and maximum likelihood estimation can be challenging. This
is especially true when the times between visits are sufficiently large that multiple transitions might
occur. An additional caveat is that model checking can be difficult. We examine these issues in the
application in Section 5.2.
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3.6 COVARIATES AND REGRESSION MODELS
With continuously observed but right-censored data, regression with fixed covariates is in principle
easy. Multiplicative Markov models having
λk`(t|H(t)) = qk`0(t) exp(X ′βk`) (7)
are widely used, and recent developments in the theory and related software for additive models have
also increased their popularity (e.g. Aalen et al., 2008, Ch. 4).
With intermittently observed processes the general situation is more difficult, because the likeli-
hood function (2) does not factor into separate pieces for each type (k, `) of transition. Estimation
when there are several covariates becomes a high-dimensional optimization problem and maximiza-
tion of the likelihood function can be challenging, especially when multiple transitions between ob-
servation times may occur. Progressive models with relatively few states are much less problematic
since there are few transition types, and the transition probabilities needed when individuals progress
at most one or two states forward are straightforward to compute.
As mentioned in Section 2.2, dealing with time-varying covariates is considerably more chal-
lenging. If covariates are observed only at visit times then there are basically two options: (i) adopt
some convention whereby covariates are assumed fixed between visit times or for some maximum
acceptable period of time following assessment, and (ii) model the covariate process jointly with the
multistate process in such a way that likelihood contributions can be calculated. An example of (i)
is the “last value carried forward” (LVCF) approach, where it is assumed that X(t) = X(vr−1) for
t ∈ (vr−1, vr]. This and similar approaches can be satisfactory when visit times are not too far apart
but generally they bias estimation (e.g. Raboud et al., 1993).
There is a large literature on joint models for covariate processes and single survival times or
repeated events; Tsiatis and Davidian (2004) provide an excellent review of work up to 2004. It
is generally assumed in this work that X(t) is observed only intermittently and in that case, rather
strong simplifying assumptions are needed concerning the dependency of transition intensities on the
covariate values. We outline here two approaches that are reasonably tractable.
The first approach assumes the existence of a vector α of random effects such that, given α, the
processes {Z(s), 0 < s} and {X(s), 0 < s} are independent. The transition intensities for Z(t) are
of conditional Markov form qk`(α), where for simplicity we do not accommodate the presence of
fixed covariates. In addition, we assume some model for the X(t) process, conditional on α. Letting
Z(vr) = (Z(v0), . . . , Z(vr−1)) and X (vr) = (X(v0), . . . , X(vr−1)), the likelihood function requires
terms
P{Z(vr), X(vr)|Z(vr),X (vr)} =
∫
P{Z(vr)|Z(vr), α} P{X(vr)|X (vr), α} dG(α) (8)
where G(·) is the distribution function for α. If the second term in the integrand has a tractable form
then (8) can be obtained by numerical integration.
The shared random effects model makes a strong conditional independence assumption. In ad-
dition, it implicitly assumes that given H(t), Z(t) depends on values X(s) for s > t, and that X(t)
exists after a terminal event like death has occurred. These assumptions are often undesirable, espe-
cially in the case of internal covariates (biomarkers), and we now consider an idealized but simple
modeling strategy that avoids such assumptions. The key idea is to replace X(t) with a categorical
variable X˜(t) obtained by grouping the values of X(t) into distinct levels 1, 2, . . . , G. The expanded
state space for (Z(t), X˜(t)) consists of states {(z, x), z = 1, . . . , K; x˜ = 1, . . . , G}. If we now
assume that {(Z(t), X˜(t)), t > 0} is a Markov process, then likelihood contributions
P{Z(vr), X˜(vr)|Z(vr−1), X˜(vr−1)} (9)
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are readily obtained. This approach has recently been discussed by Tom and Farewell (2011) and
by earlier authors such as Kay (1986), and Gentleman et al. (1994). In contexts where the internal
covariate process is a marker of disease severity and broadly reflects the general trend in the disease
process, Markov assumptions for such joint models may be reasonable. When the covariate reflects
more transient acute disease activity the former approach may be preferred. We discuss such an
approach further in the context of models for multiple disease processes in Section 4.
4 MULTIPLE PROGRESSIVE DISEASE PROCESSES
In studies involving paired or multiple organ systems, two or more processes may be of interest. In
patients with psoriatic arthritis, onset of damage in the sacroiliac (SI) joints signals the onset of a
spondyloarthropy, an arthritic condition of the vertebral joints. Damage may occur in the left SI joint,
the right SI joint, or both. In the DCCT/EDIC study, retinopathy was measured in the left and right
eyes and interest may lie in characterizing progression in both. Interest may also lie in joint modeling
of retinopathy and nephropathy, both of which are of a vascular nature.
Let {Z1(t), 0 < t} and {Z2(t), 0 < t} denote two processes of interest; when they arise from
paired organs the parameters governing the marginal processes may be the same, but for different but
correlated processes they are not. We assume for convenience the processes have the same number
of states, as in Figure 2. Interest lies in jointly modeling the processes to estimate the association
between them, to consider the extent to which one process can be used to improve efficiency in
estimation of another, and to enhance prediction.
1 2 3
1 2 3PROCESS 1
PROCESS 2
Figure 2: State space diagram for two parallel processes
Random effects modeling is often used. Let Hr(t) = {Zr(s), 0 < s < t,X} denote the history for
process r in the case where there are fixed covariates. Let Y rj (s) = I(Zr(s
−) = j), r = 1, 2, and
λ
(r)
jk (t|Hr(t), αr) = lim
∆t↓0
P (Zr(t+ ∆t
−) = k|Y rj (t) = 1,Hr(t), αr)
∆t
(10)
denote the conditional intensity of a j → k transition for process r given the random effect αr; we
assume E(αr) = 1 and var(αr) = φr. A conditional Markov model for process r has intensity of the
form
λ
(r)
jk (t|Hr(t), αr) = αrY rj (t) qjk(t;X) .
If α1⊥α2|x, then the two processes are independent given X and if α1 = α2 the random effect
is shared. If α = (α1, α2)′ follows a bivariate distribution with cov(α1, α2) = φ12 6= 0, then an
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association is accommodated for the processes. It is important to note that this does not typically lead
to easily interpreted measures of association, and the resulting marginal processes do not have simple
forms (e.g. it is not possible to have Markov models for the marginal processes after marginalizing
over the random effect), although as noted in Section 3.3, random effects models can be helpful with
intermittently observed data. However, the measures of association they imply are really only valid
with correct specification of the conditional intensities. The shared random effect model is more
easily fit (Satten, 1999), but here, however, the parameter φ is a measure of history dependence as
in (5) and also reflective of the association between the two processes, and making this model even
more problematic when interest lies primarily in association.
Another framework for joint models arises by specification of an expanded state-space defined by
combinations of the two processes; this was discussed in the context of time-varying covariates in
Section 3.6. To this end we may define transition intensities in terms of
lim
∆t↓0
P (Z(t+ ∆t−) = (j′, k′)|Z(t−) = (j, k),H(t))
∆t
= Y 1j (t)Y
2
k (t)λjk,j′k′(t|H(t))
where H(t) = {Z(s), 0 < s < t,X}. While this retains the simple form and interpretability of
multiplicative intensity-based models, we pay the price of losing direct interpretation of covariate
effects on features of the marginal processes. The same is true for more general models in which
Hr(t) in (10) is replaced byH(t). We illustrate this point in the applications of Section 5.1.
Copula functions offer an appealing framework for constructing multivariate survival models
(Nelsen, 2006), since the marginal distributions retain their simple interpretation. There has been
little work to date on the use of copula functions with multistate models, but here we outline one
such approach. Let Trk be the time of entry into state k for process r, and for illustration, consider
two 3-state processes depicted in Figure 2; we assume that each process is marginally Markov. Let
F r(t|X) = P (Tr3 > t|X) denote the survival distribution for the entry time to state 3 for process r,
r = 1, 2. In terms of the transition intensities,
F r(t|X) = P r11(t|X) + P r12(t|X)
= exp (−Qr12(t|X)) +
∫ t
0
qr12(s|X) exp (−Qr12(s|X)) exp (−Qr23(t− s|X)) ds
where P rjk(t|X) = P (Zr(t) = k|Zr(0) = j,X) and Qrk`(s|X) =
∫ s
0
qrk`(u|z)du. A copula function
C(u1, u2; τ) may be used to accommodate an association between T13 and T23 while retaining the
Markov properties of the marginal processes. More generally we can do this for the time of entry to
any state in a process. However, it is important to note that the different models for different pairs of
states will not be compatible with any single model for the full bivariate process. This approach is
most appealing when entry to a specific state is of special interest.
In some contexts interest may lie in simultaneous inferences regarding two or more processes,
but not in the association between processes. In the DCCT study, for example, the effectiveness of
the intensive glucose control program in delaying progression of nephropathy and retinopathy, was of
interest. In this case a working independence assumption can furnish parameter estimates of effects
on the marginal processes and robust sandwich-type variances estimates can be used to ensure valid
simultaneous inferences regarding two or more processes. Lee and Kim (1998) describe such an
approach for interval-censored data when the marginal processes are Markov; this approach is similar
in spirit to the Wei et al. (1989) approach for multivariate failure time data.
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5 ANALYSES AND EMPIRICAL STUDIES
5.1 AXIAL INVOLVEMENT IN PSORIATIC ARTHRITIS
Here we consider a joint analysis of the onset and progression of damage in the sacroiliac (SI) joints
among patients in the University of Toronto Psoriatic Arthritis Cohort with normal SI joints at clinic
entry. Damage was assessed radiologically at visits scheduled biannually using the modified Stein-
brocker method (Rahman et al., 1998). A joint was classified in state 1 if it was normal or if there was
soft tissue swelling. Joints showing early signs of damage through surface erosions were classified
in state 2, and joints with clinically important damage including joint space narrowing or “disorga-
nization” were classified in state 3. The left and right SI joints were assessed at each radiological
examination. The analysis here is for 538 patients who had two or more examinations.
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Figure 3: Plots of damage state for left (cross) and right (circle) sacroiliac joints with erythro sedi-
mentation rates (ESR; mm/hour) for two individuals for the University of Toronto Psoriatic Arthritis
Cohort
Figure 3 contains a plot of data from two individuals with roughly thirty years of follow-up and
frequent measurement of the inflammatory biomarker erythro sedimentation rate (ESR). Individual A
(on the left) experienced a long period of time with an elevated ESR value and both SI joints were
observed to enter state 3; individual B (on the right) had consistently low values of ESR and no
damage developed in the left or right SI joints over a period of 30 years.
Table 1 contains estimates from separate analysis of damage in the left (r = 1) and right (r = 2)
SI joints. The set-up is as in Figure 2 and we fitted separate time-homogeneous Markov models as
well as non-homogeneous models for which the transition intensities were piecewise-constant. The
naive standard errors are relevant for inferences regarding the left or right SI joints themselves, but
the robust covariance matrix would be required if interest lay in simultaneous inferences regarding
the two processes. This would also be the case if regression models were specified and interest lay in
joint inferences across the left and right sides.
The Markov model with piecewise constant intensities had cut-points at 5 and 10 years; the results
are given in the bottom of Table 1. Based on this model we can test the hypothesis of time homo-
geneity. For the left SI joint we obtain a likelihood ratio statistic of 7.78 which gives p = 0.1, so
there is insufficient evidence to reject the time homogeneous model. For the right SI joint we obtain a
likelihood ratio statistic of 20.64 giving p < 0.001; hence there is evidence of a need to accommodate
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time non-homogeneity in the transition intensities for the right SI joints. The p-values reported in Ta-
ble 1 are for 2 degree of freedom tests directed at the specific intensities and reveal that the evidence
against time homogeneity comes from the 1→ 2 transitions for the right SI joints.
Table 1: Parameter estimates, standard errors for transition intensities of three state model for dam-
age in left and right sacroiliac joints in patients with psoriatic arthritis (n = 538); cut points for the
piecewise constant time non-homogeneous model are 5 and 10 years
LEFT (r = 1) RIGHT (r = 2)
Parameter EST. S.E. EST. S.E.
TIME HOMOGENEOUS MODEL
λ
(r)
12 0.033 0.003 0.038 0.003
λ
(r)
23 0.057 0.009 0.046 0.007
log L -540.931 -581.810
PIECEWISE-CONSTANT MODEL
λ12,1 0.039 0.005 0.054 0.006
λ12,2 0.031 0.007 0.021 0.006
λ12,3 0.022 0.005 0.023 0.006
p-value∗ 0.0871 0.0001
λ23,1 0.092 0.028 0.054 0.018
λ23,2 0.043 0.017 0.037 0.014
λ23,3 0.050 0.013 0.047 0.011
p-value∗ 0.2384 0.7883
log L -537.039 -571.492
p-value∗ is for a 2 d.f. test of the null hypotheses of a time-homogeneous intensity for the respective
transition and joint
Figure 4 shows the state-space diagram for a joint Markov model for the left and right SI joints.
From this we can estimate the 9 × 9 transition intensity matrix and extract features of the marginal
processes. If we let Z(t) = (Z1(t), Z2(t)) where {Zr(s), 0 < s} is the process for the left (r = 1)
and right (r = 2) SI joints, then for example
P (Z1(t) = j|Z(0) = (1, 1)) =
3∑
k=1
P (Z(t) = (j, k)|Z(0) = (1, 1)) .
Figure 5 shows estimates of the marginal probabilities of damage for the left and right SI joints
from a non-parametric estimate of the time to entry into state 3 (Turnbull, 1976), the probability
P (Zr(t) = 3|Zr(0) = 1) from the marginal analysis, and the corresponding probability from the
joint analysis based on the 9-state model. There is good agreement between the three estimates,
particularly for the first 10 years of follow-up. The joint model is more reflective of the history of the
two processes, and enables one to characterize the dependence between the processes in a convenient
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way. For example, if as before Njr(t) = I(Tjr < t), we may write
λjk,j+1,k(t|H(t)) = λ(1)j,j+1(t) exp
(
δj2N12(t
−) + δj3N23(t−)
)
and
λjk,j,k+1(t|H(t)) = λ(2)k,k+1(t) exp
(
γk2N12(t
−) + γk3N13(t−)
)
,
where λ(1)j,j+1(t) is the baseline intensity for transitions into state j + 1 for left SI joints, δj2 is the
log relative intensity reflecting the effect of mild damage in the right SI joint (versus no damage)
on j → j + 1 progression in the left SI joint; δj3 reflects the further change in the intensity for
progression in the left SI joint when the right SI joint has clinically important damage. If we let δ =
(δ12, δ13, δ22, δ23)
′ and γ = (γ12, γ13, γ22, γ23)′, then testing H0 : δ = γ = 0 is a test of independence
of the two processes; under H0, the so-called naive analyses in Table 1 are valid. Aalen et al. (2008)
and Aalen (2012) give a nice discussion about the utility of this model for conducting causal inference
in the Granger school (Granger, 1969) through studying the nature of local-dependence.
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Figure 4: State space diagram for joint process for damage in left and right sacroiliac joints among
patients with psoriatic arthritis
Relative risks are given in Table 2 based on δ and γ, where it is evident that progression of damage
in one side has a highly significant effect on progression in the other side. For example, individuals
with moderate damage (state 2) in the right SI joint have a highly significant 16-fold higher risk of
moderate damage developing in the left SI joint. There is an insignificant further increase in risk
upon occurrence of clinically important damage on the right, but there is very little information in
the data concerning this. Those with clinically important damage on the right have a significant 9-
fold increased risk of developing clinically important damage in the left over persons with moderate
damage on the right. Interestingly there is evidence that any damage on the left side leads to higher
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Figure 5: Plot of the cumulative probability of state 3 damage for the left and right SI joints from
separate non-parametric analyses of time to State 3, separate marginal Markov models, and a joint
9-state Markov model
transition rates on the right side for all transitions with the exception of state 3 damage for 2 → 3
transitions.
An appealing feature of this formulation over a random effect formulation is that it accommodates
an asymmetric dependence. If γ = 0, then the status of process 2 does not alter risks of progression
in process 1, but if δ 6= 0, changes in process 1 alter intensities for process 2. Such a structure is not
accommodated in standard random effect models where associations are presumed to be symmetric
and arise because of latent traits that have common effects; modification are possible which weaken
the assumption of symmetry, but such models are not as appealing when interest lies in a more detailed
understanding of dependencies.
Gamma random effects models as described in Section 3.3 were also fitted, separately for the left
and right SI joints, and then a joint model as described in Section 4. In the separate fits, the variance
parameter quantifies the dependence on ti1 on the intensity of 2 → 3 transitions as shown in (5). In
both the left and right SI joints there is significant evidence of dependence; the null value in a test
of H0 : φ = 0 is on the boundary of the parameter space and so the likelihood ratio statistic is a
50 : 50 mixture of a point mass of zero and a χ21 distribution; tests of H0 : φ = 0 yield p = 0.0011
and p < 0.0001 for the left and right SI joints, respectively. The (baseline) intensities in the time-
homogeneous model and the corresponding parameters in gamma random effects models are not
strictly comparable, however it is noteworthy that the rates of 2 → 3 transitions are higher than the
1 → 2 transitions in Table 1, but not in Table 2; this is a consequence of the form of (5). In the joint
model the estimated transition intensities are broadly similar to those of the separate fits, but here the
estimate of φ is considerably larger. This is in part a consequence of the dual role of φ in this model;
it serves both as a measure of dependence as in (5) but also as a measure of association between the
two processes. As discussed earlier, this makes interpretation of φ more challenging in this setting.
Techniques for modeling the development of axial involvement in psoriatic arthritis were consid-
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Table 2: Multiplicative measures of local dependence between left and right SI joints from the 9-state
Markov model
Effect of Complementary
Side Transition Type Side State RR 95% CI p−value
Left 1→ 2 2 vs. 1 16.418 (9.598 28.082) < 0.0001
3 vs. 2 0.029 (0,∞) 0.8351
2→ 3 2 vs. 1 0.530 (0.186, 1.511) 0.2347
3 vs. 2 9.391 (4.400, 20.045) < 0.0001
Right 1→ 2 2 vs. 1 4.707 (2.422 9.146) < 0.0001
3 vs. 2 10.777 (4.421 26.271) < 0.0001
2→ 3 2 vs. 1 18.927 (1.429 250.754) 0.0257
3 vs. 2 0.281 (0,∞) 0.9328
Table 3: Estimates from fitting separate and joint gamma random effects models to left and right SI
joints
LEFT RIGHT JOINT
Parameter EST. S.E. EST. S.E. EST. S.E.
Left λ(r)12 0.046 0.007 0.070 0.011
λ
(r)
23 0.035 0.008 0.025 0.005
Right λ(r)12 0.064 0.010 0.094 0.014
λ
(r)
23 0.026 0.005 0.022 0.004
Variance φ 1.629 0.649 2.175 0.658 4.555 0.621
log L -535.602 -572.103 -995.8464
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ered by Chandran et al. (2010), who modeled a composite outcome based on left and right SI joints;
they found a broadly comparable cumulative risk of spondylitis but did not explore the relation in
progression in the left and right sides. Finally, we recommend the reader to O’Keeffe et al. (2011)
who give an extended discussion on the progression of joint damage for persons in the PsA cohort
considered here, focusing on joints in the hands. They use multistate models and, among other things,
consider the possibility of causal relationships.
5.2 MODELS FOR DIABETIC RETINOPATHY
We examine here some features associated with the progression of retinopathy in persons randomized
to treatment in the DCCT trial introduced in Example 1.2. There were two cohorts in the DCCT: a
Primary Intervention prevention (PI) cohort consisting of 726 individuals with no retinopathy and dia-
betes disease duration of 1–5 years at recruitment, and a Secondary Intervention (SI) cohort consisting
of 715 individuals with mild retinopathy and disease duration of 1–15 years at recruitment.
Within each cohort individuals were randomized to Intensive Therapy (IT) or Conventional Ther-
apy (CT) treatments; the experimental IT involved the administration of insulin three or more times
daily and was intended to maintain blood glucose concentrations at close to normal levels. Within
the primary prevention cohort, 348 (48%) individuals were randomized to the intensive therapy and
within the secondary intervention cohort 363 (51%) were randomized to the intensive therapy. Re-
cruitment occurred over 1983–1989 and subjects were followed until the termination of the trial in
1993. The Diabetes Control and Complications Trial Research Group (1993, 1995) describes findings
from the trial concerning the progression of retinopathy and other complications, and concludes that
while intensive therapy does not prevent retinopathy, it slows its progression.
The ETDRS scale used to measure retinopathy is the “final” scale in the DCCT (1995). It has
23 levels but this can be reduced to 12 levels for our purposes, with the final level 12 interpreted as
12 or higher. Broadly, level 1 is no retinopathy, levels 2 and 3 represent mild retinopathy, levels 4–9
represent increasing levels of moderate retinopathy, and levels 10 and over represent severe retinopa-
thy. The measures here represent composite scores based on the assessment of both eyes, and as we
discuss, there is considerable variation in ETDRS scores both within and between individuals. In
DCCT (1993) an outcome termed “progression” was defined as a sustained change in ETDRS over
consecutive semi-annual visits of three or more levels from the baseline measurement (at recruitment),
and this was used for treatment comparisons. All individuals in the PI cohort had ETDRS = 1 (no
retinopathy) at baseline and so for them “progression” represents a move to level 4 or higher. Later,
in the DCCT (1995), the primary outcome for the PI cohort was defined as the first occurrence of
an ETDRS score of 2 or higher on two consecutive 6-monthly visits. Our discussion here will focus
on the issue of defining progression and, more specifically, primary outcomes for the comparison of
treatment groups. For simplicity we will focus on the PI cohort.
We consider data from the DCCT followup period for the 651 white subjects among the 726 who
were randomized to treatment in the PI cohort. Box plots of the ETDRS scores at 6-monthly follow-
up visits for each treatment group (see Figure 6) show that median scores slowly move upwards over
time, starting at level 1 and reaching level 2 in the IT group and level 4 in the CT group at 9 years
from the start of the study. Variability at any given time is substantial.
Figure 7 shows plots of successive ETDRS scores for four individuals from each of the IT and
CT groups. The scores for an individual are expected to increase over time, but there is considerable
variability. In particular, an individual may show improvement (a lower ETDRS) from one visit to the
next; this can be due to variation in the assignment of a discrete score on the basis of photos of the
eyes, and to natural fluctuations in the condition of each eye.
We will explore progression of retinopathy through multistate models based on ETDRS scores.
Multistate models have not been used in previous papers on retinopathy in this study. Such models
provide a clearer picture of the longitudinal patterns of ETDRS scores and the trade-offs in defining
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Figure 6: Box plots of the ETDRS scores for the CT (Blue Box) and IT (Red Box) treatment group.
Lines show minimum, Q25, median, Q75 and maximum scores; Diamond denotes the average value
of ETDRS; Numbers denotes the total number of individuals in the indicated visit
an event termed “progression”. We begin with three-state models in which state 1 = ETDRS 1–3,
state 2 = ETDRS 4–9 and state 3 = ETDRS 10 or higher; the states correspond roughly to no or mild,
moderate and severe retinopathy, respectively. One advantage of this categorization is that everyone in
the PI cohort starts in state 1, and a move to state 2 corresponds to an increase in ETDRS of 3 or more
from baseline, consistent with the early definition of progression (DCCT, 1993). However, diagnostic
checks suggested that models with more states would be preferable, and we report here on 5-state
models with states as follows: 1 =ETDRS 1, 2 =ETDRS 2–3, 3 =ETDRS 4–6, 4 =ETDRS 7–9,
and 5 =ETDRS ≥ 10. Given the variability in longitudinal ETDRS patterns exemplified in Figure 7,
there is no clearly superior way to specify a single outcome that can be used for treatment comparisons
even in the PI cohort. We consider here a number of Markov models and then discuss their utility as
follows: Model M1 – transitions from states to any adjacent states are possible (reversible Markov
model, RMM); Model M2 – only transitions from a state to the next higher state are possible, and once
an individual progresses to the next higher state they stay there (progressive Markov model, PMM);
Model M3 – the same as M2 but a person is considered to have progressed to the next state only
when they have been in the state for two consecutive 6-monthly visits (sustained progressive Markov
model, SPMM); Model M4 – a hidden Markov model in which the true retinopathy state follows the
progressive 5-state model but where the observed state at any time is considered an imperfect measure
of the true state (Jackson and Sharples, 2002; Jackson et al., 2003).
For the 651 white subjects who were randomized to treatment in the PI cohort, we now consider
separate models for the two treatment groups (Conventional - CT, Experimental - IT). It was apparent
from fits of time-homogeneous Markov models that some time-dependence should be incorporated,
and we discuss results here for models in which the intensities were constants over 0-4 years from
randomization and (different) constants beyond 4 years. Table 4 shows parameter estimates from
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Figure 7: Profile plots of two individuals in the primary intervention cohort: IT (Left Panel) and CT
(Right Panel) group
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models M1 to M3. Plots of observed transition counts (not shown) show that the reversible Markov
model M1 mimics the observed data quite well and it reflects the fact that many subjects in each group
move both up and down between states over time.
The downward transition intensities are larger than the upward intensities from the same state in
most cases, indicating that a higher level of retinopathy is less likely than some degree of recovery.
An exception is that the 2 to 1 intensities are smaller than the 2 to 3 intensities after 4 years in the
CT group; this reflects the fact that eventually, many subjects (especially in the CT group) experience
some degree of retinopathy. Some transition rates involving states 4 and 5 are essentially inestimable
because almost no direct transitions were observed and to achieve estimability we restricted some
intensities to be equal (see Table 4). Models M2 and M3 were fitted to derived transition data in
which a subject is assumed to stay in a higher state from the time they move to it. The results from
the two models are similar, and there is relatively little difference whether we consider progression
to have occurred when it is first observed (M2) or when it is first observed on two consecutive visits.
Models M2 and M3 agree well with the (derived) data in terms of transition counts (results not shown).
We note that models M1, M2 and M3 use three different data sets, so it is not possible to compare
maximized log likelihoods or AIC values. Since all three provide reasonable fits to the corresponding
observed data, we now consider them as a basis for comparison of the treatment groups.
The DCCT (1993) compared the two groups by considering the time of ordinary or sustained
3-step progression of ETDRS, treating the endpoint as a survival time. This can also be done using
models M2 or M3, by considering time to entry to state 3; in either model the probability of entry to
state 3 by time t is given by P13(t) + P14(t) + P15(t). Figure 8 shows plots based on model M2 and a
nonparametric estimate that treats time of first entry to state 3 as interval-censored (Turnbull, 1976).
Plots for sustained progression (Model M3) in the bottom panels of Figure 8 look very similar.
There is a substantial difference between the treatment groups, with the intensive treatment associ-
ated with much slower progression. We also show in the top two panels of Figure 8 the estimated
distribution of time to first entry into state 3 based on the reversible model M1. These estimates are
well above the other two. This is at least in part due to the intermittent (6-monthly) observation of
retinopathy. Model M2 assumes that the first entry to state 3 is when it is first observed; however, it is
possible that first entry occurred earlier but was unobserved because the individual returned to state 2
(or 1) before the next observation time. Model M1 allows for this and the estimates in Figure 8 reflect
the fact that first entry to state 3 may precede the first observed entry. An “intermediate” reversible
model in which transitions from state 2 to state 1 are allowed but not transitions from state 3 to state
2, gives estimates close to those from model M2.
An examination of transition intensities in models M1 to M3 provides additional comparisons and
if desired, a formal test of no treatment effect can be based on the hypothesis of no difference between
the two groups. For M2 and M3 the IT group has intensities over the first 4 years that are comparable
to those for the CT group; this is consistent with the observation of some initial worsening in the
IT group (The Diabetes Control and Complications Trial Research Group, 1998). After 4 years all
IT group intensities are substantially lower than the CT intensities, indicating a slowing of the rate
of progression at all stages of retinopathy. The reversible model M1 better represents the observed
patterns in the ETDRS scores, but does not provide simple treatment comparisons. However, as would
be expected, the tendency to move down a state decreases with time, and tends to be higher in the IT
group, but the tendency to move up is, after the first few years, lower in the IT group.
The hidden Markov model M4 was also fitted to the raw data. It gives substantially lower rates
of progression to states 2 and 3 for the IT group than for the CT group; the results are qualitatively
similar, but not directly comparable, to those for models M2 and M3. Model M4 is not very ap-
pealing here because it compares treatments in terms of an unobservable process. In addition, some
of the misclassification probabilities are rather large, reflecting not just measurement error but also
the substantial up and down fluctuations in actual ETDRS scores. A further complication is that the
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misclassification probabilities could be expected to vary with time, because as time passes many in-
dividuals are expected to “progress” within a state in the sense that they are more likely to have an
ETDRS score at the top end of the range for the state. It is considerably more difficult to fit models
with this feature. The interpretation of parameter estimates in fitted models M4 is therefore awkward
and we do not show them in Table 4.
In the PI cohort considered here, everyone began with an ETDRS score of 1 whereas in the SI
cohort subjects had higher scores at baseline. The specification of a treatment effect is more complex
in this case. In addition, there were few persons in the PI cohort who progressed to ETDRS scores of
10 or higher during DCCT followup; more information about progression to higher scores is present
in the SI cohort and in the EDIC study that follows the DCCT. The analysis just described did not
consider covariates because we want to focus on progression and on the comparison of treatment
groups. Analyses directed at understanding the disease process would incorporate covariates and in
particular, the time-varying biomarker glycosylated hemoglobin percentage (HbA1c). It is predictive
of retinopathic progression, and the intensive therapy was designed to maintain glucose levels and
this biomarker at near normal levels. An assessment of treatment within models that contain HbA1c
is complicated because treatment affects the biomarker. One option is to define direct versus indirect
treatment effects in the sense described by Aalen et al. (2008, Section 9.3.2). However, the net effect
of treatment on retinopathy, whether acting through HbA1c or otherwise, is clear from the marginal
models considered above.
6 OUTCOME-DEPENDENT OBSERVATION AND SELECTION PROCESSES
In many settings an individual’s selection for a study, or the chance of premature loss to followup
(LTF) or missing data, may depend on their disease process. A thorough discussion of these issues is
beyond our present scope but because of their importance we discuss a few key points.
6.1 OUTCOME-DEPENDENT INSPECTION TIMES OR LOSS TO FOLLOWUP
We first consider the case where observation times, v1 < · · · < vn for an individual are prespecified.
Using the notation of earlier sections, we suppose that models for P (Z(vr)|H(vr)) are of interest,
and that if there is no missing data the likelihood function (2) provides consistent estimation of model
parameters θ0. To allow for missed visits we let R(vr) equal 1 if the individual is seen at time vr and
0 otherwise. To discuss LTF, suppose that an individual is treated as LTF (not seen again) at the first
time vr with R(vr) = 0. Provided that R(vr) is conditionally independent of Z(vs) and X(vs) for
s ≥ r, given H(vr), we can use the censored partial likelihood analogous to (2):
L(θ) =
C∏
r=1
P (Z(Vr)|H(vr); θ) , (11)
where C = max(vr : R(vr) = 1). If the preceding SMAR conditional does not hold but there exists a
vector Xc(t) of observed explanatory variables such that R(vr) is conditionally independent of Z(vs)
and X(vs) for s ≥ r, given Xc(vr) and H(vr), then inverse probability of censoring weights (IPCW)
can be used to adjust the log-likelihood or score components from (11). This requires specification of
a model for R(vr) given H(vr) and Xc(vr) (Robins et al., 1995; Hajducek and Lawless, 2012).
If an individual misses occasional visits, considerable information might be lost if they are treated
as LTF at the first missed visit. A SMAR assumption, that Z(vr) and R(vr) are conditionally in-
dependent given H(vr), in principle allows “non-monotone” missing data patterns to be handled by
maximum likelihood (e.g. Fitzmaurice et al., 2009, Chapters 17, 22) but this is often intractable. In
recent work on multistate models (e.g. Chen et al., 2010; Sweeting et al., 2010) likelihood functions
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Figure 8: Plots of the probability of entering state 3 (ETDRS 4 − −6) over time for conventional
therapy group (left panels) and experimental therapy group (right panels) using the estimates obtained
from fitting time non-homogeneous M1 (reversible Markov model), M2 (progressive Markov model),
and M3 (sustained progressive Markov model) with corresponding nonparametric estimates
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Table 4: Estimates of transition intensities and 95% confidence intervals for reversible Markov
model, progressive Markov model, and sustained progressive Markov model fitted to data from the
primary prevention cohort in the DCCT period (n = 651); cut point for the piecewise constant time
non-homogeneous model are 4 years
CONVENTIONAL EXPERIMENTAL
Model† Period Parameter EST. 95% CI p∗ EST. 95% CI p∗
M1 [0, 4) λ12 0.496 (0.442,0.557) < 0.0001 0.557 (0.492,0.630) 0.4934
λ21 0.825 (0.705,0.967) 0.0008 1.082 (0.931,1.259) < 0.0001
λ23 0.348 (0.262,0.463) < 0.0001 0.233 (0.158,0.343) 0.0635
λ32 2.032 (1.458,2.833) 0.0002 2.637 (1.752,3.969) 0.2425
λ34 = λ
‡
45 0.144 (0.033,0.622) 0.7700 0.118 (0.020,0.699) 0.9836
λ43 = λ
‡
54 3.069 (0.481,19.573) 0.5413 0.749 (0.001,669.887) 0.8718
[4,∞) λ12 1.084 (0.907,1.295) 0.512 (0.417,0.627)
λ21 0.511 (0.407,0.640) 0.398 (0.314,0.504)
λ23 0.706 (0.586,0.850) 0.376 (0.275,0.514)
λ32 0.925 (0.727,1.175) 1.905 (1.352,2.686)
λ34 = λ
†
45 0.182 (0.109,0.305) 0.115 (0.044,0.300)
λ43 = λ
‡
54 1.648 (0.844,3.218) 0.424 (0.114,1.570)
log L -2762.282 -2173.535
M2 [0, 4) λ12 0.326 (0.288,0.368) 0.0443 0.344 (0.302,0.392) 0.6939
λ23 0.135 (0.105,0.174) < 0.0001 0.074 (0.053,0.103) 0.8075
λ34 = λ
†
45 0.029 (0.008,0.112) 0.3181 0.037 (0.009,0.142) 0.7689
[4,∞) λ12 0.478 (0.338,0.675) 0.317 (0.215,0.467)
λ23 0.273 (0.218,0.341) 0.079 (0.054,0.116)
λ34 = λ
†
45 0.062 (0.037,0.101) 0.028 (0.009,0.084)
log L -1388.908 -992.704
M3 [0, 4) λ12 0.251 (0.220,0.285) < 0.0001 0.271 (0.237,0.311) 0.9435
λ23 0.133 (0.099,0.177) 0.0030 0.080 (0.055,0.114) 0.7655
λ34 = λ
†
45 0.038 (0.010,0.153) 0 .6992 0.020 (0.003,0.141) 0.7724
[4,∞) λ12 0.513 (0.386,0.681) 0.267 (0.180,0.396)
λ23 0.235 (0.186,0.296) 0.073 (0.049,0.109)
λ34 = λ
†
45 0.051 (0.028,0.093) 0.028 (0.009,0.086)
log L -1348.579 -985.507
† M1 - Reversible Markov model; M2 - Progressive Markov model; M3 - Sustained Progressive
Markov model. ‡ Parameters constrained to be the same. ∗ p−value for test of time homogeneity in
corresponding transition intensity.
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involve multiple sums over states Z(vr) at times vr with R(vr) = 0; for complex models and general
patterns of missingness these are complicated to compute unless the total number of visits n is small.
When observation times are widely spaced it is likely that SMAR assumptions are at least to
some extent violated, with the probability of a missed visit at vr depending on disease history or
covariate values over the interval (vr−1, vr]. Many authors (including Chen et al., 2010 and Sweeting
et al., 2010) have proposed “not missing at random” (NMAR) models, typically through parametric
assumptions about the distribution of R(vr) given Z(vr) and H(vr). However, such models cannot
be checked using the observed data (Fitzmaurice et al., 2009, Ch. 22). NMAR models are sometime
useful for sensitivity analysis concerning LTF (e.g. Barrett et al., 2011; Lawless, 2012) but in settings
with complex patterns of missingness the models are generally so complex that transparent sensitivity
analysis is impossible. It is best to minimize the occurrence of missing data, and to identify and record
covariates that make SMAR assumptions plausible.
In observational studies the visit times vir may vary widely within and between individuals. If
it can be assumed as in Section 2.2 that vir is scheduled on the basis of data observed up to time
vi,r−1 then the likelihood function (2) holds in the absence of LTF. If there are wide departures from
scheduled visit times then NMAR concerns arise. For example, Lawless et al. (2001) consider a
cohort of children with hydrocephalus, with individuals scheduled to return for clinic visits every 6
or 12 months. However, at the administrative end of follow-up for a particular study it was found that
many individuals had not been seen for over two or three years. In such cases it is useful to budget for
tracing of some such individuals; Farewell et al. (2003) describe this in connection with a psoriatic
arthritis cohort.
6.2 OUTCOME-DEPENDENT SELECTION
Chronic disease studies often involve conditions for recruitment. Suppose that an individual expe-
riences onset of a chronic disease process at age a0 and that they are selected for a study at age a1.
If a1 ≤ a0 we have full prospective information on disease history (subject to right censoring) and
inference can be based on P (H(t), t > a0|H(a0)), where H(a0) includes covariates related to se-
lection conditions. If a1 > a0 the prospective likelihood based on terms P (H(t), t > a1|H(a1))
can be used, subject to the availability of relevant information in H(a1), as discussed in Section 3.2.
Matters are much more complicated if we wish to use data or the disease process prior to selection
as a response; this can occur when there are rich retrospective data and the duration of followup
after selection is limited. For example, Kvist et al. (2010) describe studies on hospitalization of
persons with psychiatric affective disorders. In one study (Kessing et al., 2004) individuals were
included if they were admitted to a specific set of hospitals during the years 1959 to 1963. They
were followed forward until 1989, but data on disease history and admissions prior to 1959 were also
available from medical records. If we wish to treat all of the data for an individual as a response
instead of just the data following their (initial) admission during 1959–1963, we need to consider
P (H(a3)|H(a0), at least one admission in 1959−1963), where a3 is the individual’s age at the end of
1989. Except in special cases involving simple progressive disease models (e.g. Copas and Farewell,
2001), there has been little study of effective ways to deal with such likelihoods.
6.3 OUTCOME-BASED SUBSAMPLING
Outcome-based subsampling is frequently used for the measurement of expensive covariates of se-
lected members of a cohort. For studies involving a single event or survival time, case-cohort and
case-control designs are familiar and methods of analysis based on Cox models have been developed
(e.g. Samuelsen et al., 2007; Breslow et al., 2009). For example, some studies of the genetics of kid-
ney disease in Type 1 diabetics have selected cohort members with short times to severe nephropathy
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(“cases”) and members without severe nephropathy (“control”) for genotyping (e.g. Mueller et al.,
2006).
The use of similar designs in connection with more complicated disease history models has re-
ceived little attention. For example, consider a simple plan where at a common visit time vr a subset of
cohort members is selected and variablesW are measured on them. LetR = 1 indicate that individual
i is selected and R = 0 that they are not, and for convenience let Z and X refer to an individual’s
full history {Z(vs), X(vs), s = 0, 1, . . . , n} before and after vr. Assuming that R depends only on
observed information in (Z,X) up to time vr, the likelihood function
L = {P (Z,X|W )g(W )}R{P (Z,X)}1−R (12)
can be used (e.g. Lawless et al., 1999), where g(W ) is the probability mass function for W in the
cohort, assuming for simplicity that W is discrete. There are challenges in using (12), however. In
particular, we need to specify and estimate g(w), since
P (Z,X) =
∑
w
P (Z,X|w)g(w) .
In addition we need to consider how P (Z,X|w) is modeled. If we are primarily interested in
P (Z|X,w) then it is necessary to specify a model for P (X|w) in order to compute (12). In cases
where X involves time-varying factors this may be of some interest. If X represents only baseline
factors, then an alternative to modeling P (X|w) is to model g(w|X) = P (W = w|X = x) and to
replace (12) with a likelihood conditional onX . Alternatives that involve weighted and/or augmented
estimating function methods provide other options that have not been investigated much in the current
framework. Breslow et al. (2009) and Lumley et al. (2011) provide examples involving single event
times.
7 DISCUSSION
Multistate models offer a convenient framework for the analysis of chronic disease processes and
there are many excellent review papers on this theme (Commenges, 1999; Hougaard, 1999; Ander-
sen, 2002). Intensity-based models can provide very useful information on the dynamic aspects of a
disease process including the nature of the dependence on previous events and the effect of internal
and external time-varying covariates. Undertaking such an analysis requires careful thought about
how best to formulate models, including how to define states, which time scale to adopt, how to for-
mulate the dependence on covariates, etc. Fitting semiparametric models is particularly challenging
with interval-censored data but convenient flexible alternatives include methods based on piecewise-
constant baseline intensities; Joly et al. (2002) develop intensity-based methods based on splines.
Heterogeneity poses another modeling challenge and when random effects models are adopted care
must be taken to ensure inferences about heterogeneity are not unduly influenced by misspecification
of the model conditional on the random effects. When multiple aspects of a disease process are of
interest, as in the survival setting, simultaneous inference can be based on (correlated or shared) ran-
dom effect models, copula models or models based on a “working independence” assumption with
robust variance estimates.
Model assessment has not been discussed in this paper. In general, we recommend this be done
through the usual device of model expansion, particularly when there are covariates. In settings where
processes are observed continuously, residual plots and other techniques for model assessment in
survival analysis can be used, since sojourns in a state are equivalent to survival times in a competing
risk model. When Markov models are adopted for processes under intermittent observation, it is
possible to compare expected (model-based) transition counts and corresponding observed counts in
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some cases (Titman and Sharples, 2010b), and some such checks are provided by the msm package
(Jackson, 2011). Further exploration of model checking methods would be valuable.
Many progressive chronic diseases involve a gradual deterioration in the function of one or more
organ systems (e.g. eyes, kidneys) over a long time horizon. When assessments are carried out fre-
quently, data suggesting a short-term improvement may be obtained and decisions are required about
how to handle such information. Reasons for the apparent improvement include a legitimate rever-
sal of the underlying condition or an imperfect measurement process leading to spurious evidence of
improvement. In the former case, models accommodating transitions to better health states may be
appealing, but models based on latent processes (e.g. hidden Markov models) may be preferred in
the latter. When serum or urinary markers of disease severity are to be used short-term variation may
be considerable. In studies of HIV/AIDS, for example, markers of immune function (e.g. CD4 cell
counts) have been used effectively to characterize the disease course, but these are, in some sense,
surrogate data to the more difficult to observe clinically important events. The considerable variation
in these measurements motivates the use of methods which accommodate measurement error (Satten
and Longini, 1996).
Aalen et al. (2001) and Datta and Satten (2001) showed that with right-censored multistate data
the usual Aalen-Johansen estimator of the state occupancy probabilities, motivated by Markov as-
sumptions, are robust and valid for non-Markov models when censoring is completely independent.
When states are intermittently observed nonparametric estimation based on Markov assumptions is
challenging (Frydman, 1992, 1995; Frydman and Szarek, 2009); exploration of robustness in this
context is warranted.
Regression models involving multiplicative covariate effects are routinely specified but there has
been increased interest in the use of additive models (Aalen, 1989; Martinussen and Scheike, 2006), or
hybrid models (Scheike and Zhang, 2002). There is scope for development of methods based on these
alternative specification in the context of multistate analysis. When interest lies in formally comparing
two or more treatment groups, intensity-based models are less natural since they inherently involve
conditioning on the process history through internal and responsive covariates (Kalbfleisch and Pren-
tice, 2002). Here alternative frameworks for treatment comparisons are of interest. A series of papers
beginning with Andersen et al. (2003) explored the quite different approach of using of resampling
methods and model fitting based on pseudo-observations to model covariate effects on state occu-
pancy probabilities at particular time points with right-censored data. There is some appeal to this in
that analysis is carried out as in generalized linear models and the dependencies in estimators from fits
at different time points are accommodated by use of robust variance estimates. Little work has been
done to adapt these methods to interval-censored data and this is an area warranting development.
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